-
Mashup Score: 4Optimal approach to T-cell ALL - 19 hour(s) ago
Abstract. T-lineage acute lymphoblastic leukemia (T-ALL) is curable for most children and adolescent and young adult patients with contemporary frontline chemot
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2
Treatment with blinatumomab or inotuzumab ozogamicin particularly confers higher total costs for patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet-
Investigators reported a mean total treatment cost of $513,279 for second-line therapy, $340,419 for third-line therapy, and $390,327 for treatment in the fourth line and beyond. #leusm https://t.co/KPGMm9P61W
-
-
Mashup Score: 19
Objectives To compare the efficacy of venetoclax-azacitidine (VEN–AZA) with AZA in the real-life for patients with first relapsed or refractory acute myeloid leukaemia (R/R AML). Methods We retros…
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet-
Azacitidine–venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients - Petit - European Journal of Haematology - Wiley Online Library https://t.co/6xuIq7R77t #leusm https://t.co/ndpbT7PiXc
-
-
Mashup Score: 2
The safety profile of venetoclax following allogeneic hematopoietic stem cell transplantation in patients with chronic lymphocytic leukemia appears to be comparable with other reports in clinical trials.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet-
Prior allogeneic hematopoietic stem cell transplantation did not impact the ability of venetoclax to produce objective responses among a small cohort of patients with heavily pretreated, high-risk chronic lymphocytic leukemia. #leusm | @FrancePeru https://t.co/i3SdWHgZs3
-
-
Mashup Score: 3FDA Approval Sought for Obe-Cel in Relapsed/Refractory B-ALL - 3 day(s) ago
A biologics license application seeking the approval of obecabtagene autoleucel for the treatment of adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia has been submitted to the FDA.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
.@us_fda Approval Sought for Obe-Cel in Relapsed/Refractory B-ALL #leusm https://t.co/WGIznyt1mH
-
-
Mashup Score: 0
Nicole Lamanna, MD, discusses how the use of novel agents could address resistance associated with current treatment options for patients with chronic lymphocytic leukemia.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
WATCH: Dr Lamanna, of @columbiacancer, discusses how the use of novel agents could address resistance associated with current treatment options for patients w/ CLL. #leusm https://t.co/aXZKvPRrXA
-
-
Mashup Score: 2
John N. Allan, MD, discusses the importance of understanding fixed-duration treatment approaches with BTK inhibitors and BCL2 inhibitors in patients with chronic lymphocytic leukemia, highlighting data within this treatment armamentarium.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
WATCH: Dr Allan, of @WeillCornell, discusses the importance of understanding fixed-duration treatment approaches w/ BTK inhibitors and BCL2 inhibitors in patients with CLL, highlighting data within this treatment armamentarium. #leusm https://t.co/qVHAt4cIni
-
-
Mashup Score: 1FDA Approves Jaypirca for Pretreated CLL, SLL - 6 day(s) ago
The Food and Drug Administration approved Jaypirca for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who received two or more lines of therapy.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
BREAKING: The FDA approved Jaypirca for pretreated CLL or SLL. #leusm https://t.co/4bA3EPYDAA
-
-
Mashup Score: 0FDA Gives Accelerated Approval to Pirtobrutinib in CLL/SLL - 6 day(s) ago
Patients with chronic lymphocytic leukemia and small lymphocytic lymphoma can now receive treatment with pirtobrutinib.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet-
Patients with chronic lymphocytic leukemia and small lymphocytic lymphoma can now receive treatment with pirtobrutinib. #leusm | @US_FDA @FDAOncology https://t.co/c1VPvqs8pw
-
-
Mashup Score: 2Long-term efficacy of ibrutinib–venetoclax for first-line treatment in chronic lymphocytic leukaemia - 7 day(s) ago
The results of the primary endpoint of the GLOW study1 formed the basis for approval of ibrutinib (a BTK inhibitor) and venetoclax (a BCL-2 inhibitor) combination therapy for first-line treatment of chronic lymphocytic leukaemia. This approach is now integrated in clinical practice. However, the analysis of long-term data by Carsten U Niemann and colleagues,2 after a median observation time of nearly 4 years, can address several key questions that have arisen in the context of this therapy.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet-
"Although ibrutinib–venetoclax provides long-lasting remission ... we still need evidence that ibrutinib–venetoclax might yield an efficacy similar to other standard regimens..." Linked Comment by Anna Fink. #leusm https://t.co/yPvowPcNps
-
Optimal approach to T-cell ALL https://t.co/IgxcbHNe2r #leusm https://t.co/008dL5derf